Kymera Therapeutics, Inc. Common Stock vs. Moderna, Inc. Common Stock
KYMR
Kymera Therapeutics, Inc. Common Stock
$127.31 +4.89%
VS MRNAModerna, Inc. Common Stock
$174.38 +176.97%
Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| KYMR | MRNA | |
|---|---|---|
| Market Cap | $10.09 billion | $25.14 billion |
| Revenue (TTM) | $105.00 million | $2.23 billion |
| Net Income (TTM) | $-299,601,000 | $-3,151,000,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| KYMR | MRNA | |
|---|---|---|
| Price / Book | 6.69 | 3.72 |
| Price / Sales | 96.12 | 11.28 |
MRNA leads on 2 of 2 valuation factors.
Profitability
| KYMR | MRNA | |
|---|---|---|
| Net Margin | -285.34% | -141.43% |
| Return on Equity | -19.85% | -46.61% |
KYMR and MRNA split the profitability factors evenly.
Risk & Sentiment
| KYMR | MRNA | |
|---|---|---|
| Short Interest | 0.24% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: KYMR overview, KYMR financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.